PharmaShots Connects Brands & Decision-Makers with Custom Media Solutions PharmaShots Provides Curated News & Insights for the Biopharma & Healthcare Industry PharmaShots is Empowering Decision Makers with Actionable Insights Amplify Your Brand with PharmaShots’ Expert Content Creation & Marketing Solutions PharmaShots Enables Brands to Strategically Connect with Their Target Audiences Deliver Your News to the Right Audience with PharmaShots Newswire CXO TALKS CXO TALKSPharmaShots CXO Talks | Women’s History Month Special: A Conversation with Dr. Emanuela Offidani of Tris Pharma CXO TALKSPharmaShots CXO Talks | A Conversation with Liz Benditt, Founder & CEO, The Balm Box CXO TALKSCXO Talks: Vikas Sharma Reveals QurAlis’ Bold Vision for the Future of Neuroscience CXO TALKSCXO Talks: Josh Wittner from Gene By Gene in a Riveting Conversation with PharmaShots EXCLUSIVE INTERVIEW EXCLUSIVEExclusive: A Stimulating Dialogue with Edmund Ben Ami, Co-Founder & CEO of NeuraLight EXCLUSIVEExclusive: Dr. Mónica Domínguez from Smile Train in a Stimulating Conversation with PharmaShots on Why a Healthy Mouth is a Happy Mind EXCLUSIVEExclusive: Kenneth Sake from Blueprint Medicines in an Enlightening Conversation with PharmaShots EXCLUSIVEExclusive Coverage: Dr. Ikshit Sharma from AIMIL Pharmaceuticals in a Stimulating Dialogue Exchange with PharmaShots EXCLUSIVEAdvancing Care for Hematologic Malignancies: Chris Heery from Arcellx in a Stimulating Dialogue Exchange with PharmaShots EXCLUSIVEDecoding Approval: Moitreyee Chatterjee-Kishore from Astellas in an Exclusive Conversation with PharmaShots EXCLUSIVEAdvancing Urothelial Carcinoma Care: Ahsan Arozullah from Astellas Pharma in an Exclusive Interview with PharmaShots EXCLUSIVEExclusive: David Esposito in an Illuminating Discussion with PharmaShots LATEST NEWSStay up-to-date Akeso Announces P-II (COMPASSION-26) Trial Results on Cadonilimab + CT in 1L PDAC 14 minutes ago Astellas and Pfizer Gain FDA Priority Review for Padcev + Keytruda in Muscle-Invasive Bladder Cancer (MIBC), Regardless of Cisplatin Eligibility 2 hours ago TJ Biopharma Licenses Felzartamab to Biogen for Greater China in ~$850M Deal 3 hours ago Eli Lilly to Acquire Kelonia Therapeutics for ~$7B 4 hours ago Pheast Therapeutics Reports Early P-Ia Data for PHST001 at AACR 2026 22 hours ago Novo Nordisk Reports Positive P-III (HIBISCUS) Study Data for Etavopivat in Sickle Cell Disease 23 hours ago Read More Your Daily Dose of Biopharma News & Insights Delivered to Your Inbox. Join the PharmaShots Family of 20000+ subscribers Subscribe Now
Astellas and Pfizer Gain FDA Priority Review for Padcev + Keytruda in Muscle-Invasive Bladder Cancer (MIBC), Regardless of Cisplatin Eligibility 2 hours ago
Novo Nordisk Reports Positive P-III (HIBISCUS) Study Data for Etavopivat in Sickle Cell Disease 23 hours ago
